NEIMETH — NEIMETH INTERNATIONAL PHARMACEUTICALS Disclosures

FINANCIAL HIGHLIGHTS: • PAT: ₦0.113 billion (7% YoY growth) • EPS: ₦0.0265 • Dividend: Nil • Equity: ₦2.742 billion • Shares: 4,273.104 million • ROE: 4.14% KEY NOTES: • Revenue increased by 45% YoY to ₦1.751 billion. • The Company transitioned from the cost model to the Fair Value Method for recognizing investment property in 2024 Financial Year. • The Company is subject to various pending litigations arising in the normal course of business. The contingent liabilities in respect of pending litigations based on the response received from the company solicitors' was Nill million as at 31 March 2026 (2025: N115 million).

Here's a summary of the NEIMETH disclosure: * The Board of Directors of Neimeth International Pharmaceuticals Plc. approved the Company's Unaudited Financial Statements for Q1 ended 31st March 2026 (2026, Q1 UFS). * The approval took place at a Board meeting held on Tuesday, 28th April 2026. * The 2026 Q1 UFS will be filed with the Nigerian Exchange Limited (NGX) on or before 30th April 2026. * The closed period for trading in the Company's shares by Insiders and connected persons will remain until twenty-four (24) hours after the 2026 Q1 UFS is released to the public.